We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+0.99%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$7.04M
Cap. Flow
+$4.18M
Cap. Flow %
0.41%
Top 10 Hldgs %
43.95%
Holding
94
New
9
Increased
28
Reduced
9
Closed
24

Top Buys

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$20.2M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$17.1M
3
UAM
Universal American Corp
UAM
+$12.2M
4
RAD
Rite Aid Corporation
RAD
+$11.8M
5
CORI
Corium International, Inc.
CORI
+$10.6M

Top Sells

Rank Stock Value
1
LCI
Lannett Company, Inc.
LCI
+$24.4M
2
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$21M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.9M
4
OCR
OMNICARE INC
OCR
+$10.4M
5
MOH icon
Molina Healthcare
MOH
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 79.79%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
1
DELISTED
Avadel Pharmaceuticals
AVDL
$79M 7.71%
5,267,911
– –
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$68.9M 6.72%
4,353,214
+47,745
+1% +$681K
ANGO icon
3
AngioDynamics
ANGO
$554M
$48.5M 4.73%
2,970,510
+377,861
+15% +$5.47M
EBS icon
4
Emergent Biosolutions
EBS
$391M
$46.7M 4.56%
2,080,519
+275,167
+15% +$6.41M
BDSI
5
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$40.7M 3.97%
3,372,054
-100,000
-3% -$948K
AMAG
6
DELISTED
AMAG Pharmaceuticals
AMAG
$40.6M 3.96%
1,960,775
+1,093,658
+126% +$20.2M
HRTX icon
7
Heron Therapeutics
HRTX
$88.7M
$34.6M 3.37%
2,808,173
+575,000
+26% +$6.87M
ASRT
8
DELISTED
Assertio
ASRT
$34.4M 3.35%
41,195
-11,985
-23% -$9.23M
PGNX
9
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$28.6M 2.79%
6,636,169
+1,050,000
+19% +$4.01M
TTPH
10
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$28.5M 2.78%
105,787
+5,381
+5% +$1.15M
AEGR
11
DELISTED
Aegerion Pharmaceuticals
AEGR
$26M 2.54%
810,044
+460,044
+131% +$17.1M
ANAC
12
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$25.6M 2.5%
1,443,220
+442,351
+44% +$7.12M
PTX
13
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$25.1M 2.45%
350,000
– –
TVTX icon
14
Travere Therapeutics
TVTX
$5.16B
$24.9M 2.43%
1,675,251
+65,555
+4% +$888K
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$21.1M 2.06%
1,824,377
+154,600
+9% +$1.59M
UAM
16
DELISTED
Universal American Corp
UAM
$20.7M 2.02%
2,486,459
+1,604,854
+182% +$12.2M
RIGL icon
17
Rigel Pharmaceuticals
RIGL
$739M
$20.3M 1.98%
559,802
+14,290
+3% +$486K
NVDQ
18
DELISTED
Novadaq Technologies Inc.
NVDQ
$19.8M 1.93%
1,201,617
-25,000
-2% -$412K
NTUS
19
DELISTED
Natus Medical Inc
NTUS
$19.2M 1.88%
764,915
– –
INFI
20
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$18.3M 1.79%
1,438,484
+112,484
+8% +$1.17M
IPXL
21
DELISTED
Impax Laboratories, Inc.
IPXL
$18.3M 1.78%
608,929
-25,000
-4% -$674K
ATRC icon
22
AtriCure
ATRC
$1.77B
$18.1M 1.77%
985,193
+272,698
+38% +$4.54M
WINT
23
DELISTED
Windtree Therapeutics Inc
WINT
$14.4M 1.4%
576,143
– –
PETX
24
DELISTED
Aratana Therapeutics, Inc.
PETX
$12.8M 1.24%
817,435
+150,000
+22% +$2.13M
DVAX
25
DELISTED
Dynavax Technologies
DVAX
$12.3M 1.2%
766,010
– –
1
2 3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Broadfin Capital held 94 positions worth $1.03B, down 0.68% from $1.03B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Broadfin Capital's Q2 2014 filing shows 9 new, 28 increased, 9 reduced and 24 closed positions. Its largest new stake was Rite Aid Corporation: 80,000 shares worth $11.5M. The largest sale was Lannett Company, Inc., an estimated $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 80% a quarter earlier, followed by Technology.

  • Broadfin Capital's largest Q2 2014 buy was Rite Aid Corporation: 80,000 shares worth $11.5M.
  • Broadfin Capital added most to AMAG Pharmaceuticals in Q2 2014, an estimated $20.2M increase.
  • Broadfin Capital's biggest Q2 2014 reduction was Assertio, cutting an estimated $9.23M.
  • Broadfin Capital fully exited Lannett Company, Inc. in Q2 2014, selling an estimated $24.4M.
  • Broadfin Capital's ten largest holdings make up 44% of its $1.03B portfolio in Q2 2014.
  • Broadfin Capital opened 9 new positions and closed 24 in Q2 2014.
  • Broadfin Capital's portfolio value fell 0.68% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2014, filed 14 Aug 2014.